July 28, 2022

Labcorp to spin off clinical development business

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 28, 2022-- Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction.
February 21, 2022

Labcorp completes acquisition of Personal Genome Diagnostics

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 21, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. ( PGDx ), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
December 3, 2021

Labcorp completes acquisition of Toxikon corporation

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 3, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation , a contract research organization delivering best-in-class nonclinical testing services.
<span>Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients</span>
November 18, 2021

Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.
May 3, 2021

Labcorp to acquire Myriad Autoimmune’s Vectra testing business from Myriad Genetics

BURLINGTON, N.C. --(BUSINESS WIRE)--May 3, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been completed since the product’s launch in November 2010, and a meaningful portion of testing volume currently flows through Labcorp.